Reddymasu Savio C, McCallum Richard W
University of Kansas Medical Center, Division of Gastrointestinal Motility, Department of Medicine, Kansas City, 3901 Rainbow Boulevard, KS-66160-7350, USA.
Expert Opin Pharmacother. 2009 Feb;10(3):469-84. doi: 10.1517/14656560902722505.
Gastroparesis is a relatively common and often disabling condition that is characterized by a broad range of clinical presentation ranging from dyspeptic symptoms to nausea, vomiting, abdominal pain, malnutrition, frequent hospitalizations and incapacitation. The treatment of gastroparetic symptoms can be challenging to the gastroenterologist and the intensity of therapy varies with the physician's knowledge. Hence the determination that a patient is refractory to 'standard medical therapy' is an assessment that is subspeciality-based and could differ around the world depending on medications available. In this article, we review the use of available prokinetics, antiemetic agents, the approach for analgesia in the context of gastroparesis, and also discuss potential and evolving pharmacotherapies. The progress has been relatively limited as far as availability of new medications for gastroparesis is concerned; however, active research in developing newer prokinetics holds great promise for the future of management of this challenging entity.
胃轻瘫是一种相对常见且往往导致功能障碍的病症，其临床表现范围广泛，从消化不良症状到恶心、呕吐、腹痛、营养不良、频繁住院和功能丧失。胃轻瘫症状的治疗对胃肠病学家来说可能具有挑战性，治疗强度因医生的知识水平而异。因此，确定患者对“标准药物治疗”无效是基于专科的评估，并且在世界各地可能因可用药物的不同而有所差异。在本文中，我们回顾了可用的促动力药、止吐药的使用，胃轻瘫背景下的镇痛方法，并讨论了潜在的和不断发展的药物治疗。就胃轻瘫新药的可用性而言，进展相对有限；然而，开发新型促动力药的积极研究为这个具有挑战性的疾病的未来管理带来了巨大希望。
